Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Lorigan, Paul C
Von Pawel, J
AffiliationDepartment of Pulmonary Diseases, Vrije University Medical Center, Amsterdam, The Netherlands.
MetadataShow full item record
AbstractClinical results of a randomized phase III trial comparing pemetrexed-carboplatin (PC) with etoposide-carboplatin (EC) in chemonaive patients with extensive-stage disease small-cell lung cancer (ED-SCLC) resulted in trial closure for futility; biomarker analyses using immunohistochemistry (IHC) and single-nucleotide polymorphisms (SNPs) are described herein.
CitationBiomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. 2012, 23 (7):1723-9 Ann Oncol
JournalAnnals of Oncology